Treatment of lentigo maligna with tazarotene 0.1% gel - 24/08/11
Doi : 10.1016/j.jaad.2003.07.005
Sergio Chimenti, MD a, ⁎ 
, Anna Maria Carrozzo, MD a, Luigi Citarella, MD a, Catia De Felice, MD a, Ketty Peris, MD b
, Anna Maria Carrozzo, MD a, Luigi Citarella, MD a, Catia De Felice, MD a, Ketty Peris, MD b a Departments of Dermatology, Department of Dermatology University of Rome “Tor Vergata”, Rome, Italy,
b Department of Dermatology University of L'Aquila, L'Aquila, Italy
*Reprint requests: Sergio Chimenti, MD, Department of Dermatology, University of Rome “Tor Vergata,” Viale Oxford 81, 00133 Rome, Italy.
Abstract |
We report 2 elderly patients with facial lentigo maligna who experienced complete regression, both clinically and histopathologically, after once-daily topical treatment with tazarotene 0.1% gel for 6 to 8 months. After a follow-up period of 18 and 30 months, no recurrence was observed. We believe that tazarotene might be considered as an alternative medical approach in selected patients with lentigo maligna.
Le texte complet de cet article est disponible en PDF.Plan
 | Funding sources: None. Conflicts of interest: None identified. |
© 2004
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 50 - N° 1
P. 101-103 - janvier 2004 Retour au numéro
Article précédent
- December 2003 iotafotaderma (#119)
- Nathaniel Jellinek
- Increased incidence of hypercoagulability in patients with leg ulcers caused by leukocytoclastic vasculitis
- Jan R Mekkes, Miriam A Loots, Allard C van der Wal, Jan D Bos
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?